Skip to Content
Merck
  • Should diffuse bronchiectasis still be considered a CFTR-related disorder?

Should diffuse bronchiectasis still be considered a CFTR-related disorder?

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society (2015-03-24)
Anne Bergougnoux, Victoria Viart, Julie Miro, Sébastien Bommart, Nicolas Molinari, Marie des Georges, Mireille Claustres, Raphaël Chiron, Magali Taulan-Cadars
ABSTRACT

Although several comprehensive studies have evaluated the role of the CFTR gene in idiopathic diffuse bronchiectasis (DB), it remains controversial. We analyzed the whole coding region of the CFTR gene, its flanking regions and the promoter in 47 DB patients and 47 controls. Available information about demographic, spirometric, radiological and microbiological data for the DB patients was collected. Unclassified CFTR variants were in vitro functionally assessed. CFTR variants were identified in 24 DB patients and in 27 controls. DB variants were reclassified based on the results of in silico predictive analyses, in vitro functional assays and data from epidemiological and literature databases. Except for the sweat test value, no clear genotype-phenotype correlation was observed. DB should not be considered a classical autosomal recessive CFTR-RD. Moreover, although further investigations are necessary, we proposed a new class of "Non-Neutral Variants" whose impact on lung disease requires more studies.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-Lamin A/C Antibody, clone 14, clone 14, Upstate®, from mouse
Sigma-Aldrich
Anti-CFTR Antibody, clone MM13-4, clone MM13-4, Upstate®, from mouse